Pasithea Therapeutics Corp.

A New BioTech Research Race Is Focused On Improving Life For MS Patients
Sponsored
New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope
Sponsored
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
Sponsored
New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope
Sponsored
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
Sponsored
Smaller Biotechs May Pave Way For New Generation Of Therapeutics For Hard-to-Treat Neurological Disorders
Sponsored
A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea
Sponsored

Pasithea Therapeutics Corp. Recent News

Pasithea Reveals Cash Position Of $52.9 Million In Latest Earnings Report, To Expand Pipeline And Fund Operations Well Into 2024
Image sourced from Pixabay
Sponsored
Pasithea Partners With Glimpse Group To Co-Develop VR Environments For Patients With Psychiatric Disorders
Photo by Maxim Hopman on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Sponsored
Pasithea Therapeutics Announces Plans To Open Three New Clinics In The UK By Mid-2022
-- Each clinic expected to contribute an estimated USD$5 million (£4 million) annually in revenue -- -- New London locations will provide pharmacy services, ketamine therapy, and other psychiatric treatments, including repeated transcranial magnetic stimulation (“rTMS”) --
Sponsored
From Mobile Clinics to Drug Development, This Company Is Attempting to Tackle Brain Disorders and Promote Mental Health Advances
Photo by David Matos on Unsplash
Sponsored
EXCLUSIVE: Pasithea Clinics Launches In-Home Intravenous Ketamine Therapy In Major US Cities
Pasithea Therapeutics Corp.